Cargando…
The Efficacy of Li-ESWT Combined With VED in Diabetic ED Patients Unresponsive to PDE5is: A Single-Center, Randomized Clinical Trial
INTRODUCTION: Phosphodiesterase type 5-inhibitors (PDE5is) are the first-line treatment for patients with diabetes mellitus-induced erectile dysfunction (DMED), however, some patients are non-responser to PDE5is. We performed a perspective, randomized, comparative study to explore the efficacy of lo...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259797/ https://www.ncbi.nlm.nih.gov/pubmed/35813628 http://dx.doi.org/10.3389/fendo.2022.937958 |
_version_ | 1784741863494778880 |
---|---|
author | Tao, Rongzhen Chen, Jianhuai Wang, Dujian Li, Yunpeng Xiang, Jun Xiong, Lei Ji, Junbiao Wu, Jie Zhou, Shuang Jia, Chunping Lv, Jianlin Yang, Jie Tang, Qinglai |
author_facet | Tao, Rongzhen Chen, Jianhuai Wang, Dujian Li, Yunpeng Xiang, Jun Xiong, Lei Ji, Junbiao Wu, Jie Zhou, Shuang Jia, Chunping Lv, Jianlin Yang, Jie Tang, Qinglai |
author_sort | Tao, Rongzhen |
collection | PubMed |
description | INTRODUCTION: Phosphodiesterase type 5-inhibitors (PDE5is) are the first-line treatment for patients with diabetes mellitus-induced erectile dysfunction (DMED), however, some patients are non-responser to PDE5is. We performed a perspective, randomized, comparative study to explore the efficacy of low intensity extracorporeal shock wave treatment (Li-ESWT) combined with vacuum erectile device (VED) in the treatment of DMED patients who were unresponsive to PDE5is. METHODS: One hundred and five eligible patients were randomly divided into three groups: group A (VED), group B (Li-ESWT) and group C (VED plus Li-ESWT). Follow-up was conducted at 4 weeks, 8 weeks and 12 weeks after the end of treatment. The erectile function was estimated by the international index of erectile function-erectile function domain (IIEF-EF), erection hardness score (EHS), sexual encounter profile questions 2 and 3 (SEP2 and SEP3) and global assessment question 1 and 2 (GAQ1 and GAQ2) before and after treatment. The changes of five points in IIEF-EF were calculated as the minimal clinical important difference (MCID), which was considered as the main index of efficacy. RESULTS: The MCID was achieved in 14.7%, 14.7% and 17.6% patients in group A at the follow up on 4 weeks, 8 weeks and 12 weeks, respectively (36.4%, 39.4% and 36.4% in group B; 36.4%, 51.5%, and 66.7% in group C). There were significant differences in the percentage of MCID cases between group A and group C at the follow up on 12 weeks (P<0.001), as well as that between group B and group C (P=0.014). Additionally, comparison in MCID within group C showed that there were significant differences between 4 weeks and 12 weeks follow-up (P=0.014). CONCLUSION: Our findings indicated the combined therapy Li-ESWT and VED was more beneficial to shift turn PDE5is non-responders to responders for moderate patients with DMED than VED or Li-ESWT monotherapy. Moreover, this study provided evidence that patients with DMED who failed after taking oral PDE5is could attempt to opt for an alternative physicotherapy (Li-ESWT or VED) prior to more invasive alternatives. |
format | Online Article Text |
id | pubmed-9259797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92597972022-07-08 The Efficacy of Li-ESWT Combined With VED in Diabetic ED Patients Unresponsive to PDE5is: A Single-Center, Randomized Clinical Trial Tao, Rongzhen Chen, Jianhuai Wang, Dujian Li, Yunpeng Xiang, Jun Xiong, Lei Ji, Junbiao Wu, Jie Zhou, Shuang Jia, Chunping Lv, Jianlin Yang, Jie Tang, Qinglai Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: Phosphodiesterase type 5-inhibitors (PDE5is) are the first-line treatment for patients with diabetes mellitus-induced erectile dysfunction (DMED), however, some patients are non-responser to PDE5is. We performed a perspective, randomized, comparative study to explore the efficacy of low intensity extracorporeal shock wave treatment (Li-ESWT) combined with vacuum erectile device (VED) in the treatment of DMED patients who were unresponsive to PDE5is. METHODS: One hundred and five eligible patients were randomly divided into three groups: group A (VED), group B (Li-ESWT) and group C (VED plus Li-ESWT). Follow-up was conducted at 4 weeks, 8 weeks and 12 weeks after the end of treatment. The erectile function was estimated by the international index of erectile function-erectile function domain (IIEF-EF), erection hardness score (EHS), sexual encounter profile questions 2 and 3 (SEP2 and SEP3) and global assessment question 1 and 2 (GAQ1 and GAQ2) before and after treatment. The changes of five points in IIEF-EF were calculated as the minimal clinical important difference (MCID), which was considered as the main index of efficacy. RESULTS: The MCID was achieved in 14.7%, 14.7% and 17.6% patients in group A at the follow up on 4 weeks, 8 weeks and 12 weeks, respectively (36.4%, 39.4% and 36.4% in group B; 36.4%, 51.5%, and 66.7% in group C). There were significant differences in the percentage of MCID cases between group A and group C at the follow up on 12 weeks (P<0.001), as well as that between group B and group C (P=0.014). Additionally, comparison in MCID within group C showed that there were significant differences between 4 weeks and 12 weeks follow-up (P=0.014). CONCLUSION: Our findings indicated the combined therapy Li-ESWT and VED was more beneficial to shift turn PDE5is non-responders to responders for moderate patients with DMED than VED or Li-ESWT monotherapy. Moreover, this study provided evidence that patients with DMED who failed after taking oral PDE5is could attempt to opt for an alternative physicotherapy (Li-ESWT or VED) prior to more invasive alternatives. Frontiers Media S.A. 2022-06-23 /pmc/articles/PMC9259797/ /pubmed/35813628 http://dx.doi.org/10.3389/fendo.2022.937958 Text en Copyright © 2022 Tao, Chen, Wang, Li, Xiang, Xiong, Ji, Wu, Zhou, Jia, Lv, Yang and Tang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Tao, Rongzhen Chen, Jianhuai Wang, Dujian Li, Yunpeng Xiang, Jun Xiong, Lei Ji, Junbiao Wu, Jie Zhou, Shuang Jia, Chunping Lv, Jianlin Yang, Jie Tang, Qinglai The Efficacy of Li-ESWT Combined With VED in Diabetic ED Patients Unresponsive to PDE5is: A Single-Center, Randomized Clinical Trial |
title | The Efficacy of Li-ESWT Combined With VED in Diabetic ED Patients Unresponsive to PDE5is: A Single-Center, Randomized Clinical Trial |
title_full | The Efficacy of Li-ESWT Combined With VED in Diabetic ED Patients Unresponsive to PDE5is: A Single-Center, Randomized Clinical Trial |
title_fullStr | The Efficacy of Li-ESWT Combined With VED in Diabetic ED Patients Unresponsive to PDE5is: A Single-Center, Randomized Clinical Trial |
title_full_unstemmed | The Efficacy of Li-ESWT Combined With VED in Diabetic ED Patients Unresponsive to PDE5is: A Single-Center, Randomized Clinical Trial |
title_short | The Efficacy of Li-ESWT Combined With VED in Diabetic ED Patients Unresponsive to PDE5is: A Single-Center, Randomized Clinical Trial |
title_sort | efficacy of li-eswt combined with ved in diabetic ed patients unresponsive to pde5is: a single-center, randomized clinical trial |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259797/ https://www.ncbi.nlm.nih.gov/pubmed/35813628 http://dx.doi.org/10.3389/fendo.2022.937958 |
work_keys_str_mv | AT taorongzhen theefficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT chenjianhuai theefficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT wangdujian theefficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT liyunpeng theefficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT xiangjun theefficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT xionglei theefficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT jijunbiao theefficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT wujie theefficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT zhoushuang theefficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT jiachunping theefficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT lvjianlin theefficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT yangjie theefficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT tangqinglai theefficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT taorongzhen efficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT chenjianhuai efficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT wangdujian efficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT liyunpeng efficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT xiangjun efficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT xionglei efficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT jijunbiao efficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT wujie efficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT zhoushuang efficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT jiachunping efficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT lvjianlin efficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT yangjie efficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial AT tangqinglai efficacyoflieswtcombinedwithvedindiabeticedpatientsunresponsivetopde5isasinglecenterrandomizedclinicaltrial |